Value of Antidrug Antibody Screening in Moderate-To-Severe Rheumatiod Arthritis Patients Who Failed Initial Tumor Necrosis Factor-Alpha Treatment

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.09.679
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Antidrug Antibody Formation During Tumor Necrosis Factor Α Inhibitor Treatment of Severe Psoriatic Patients in the Real-Life Practice

Postepy Dermatologii I Alergologii
DermatologyAllergyImmunology
2019English

PMS73 Visualizing Treatment Patterns of Veteran Patients With Rheumatoid Arthritis Who Initiated Tumor Necrosis Factor Therapy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

PMS5 Data Visualization of Treatment Patterns of Medicare Psoriatic Arthritis Patients Who Initiate Tumor Necrosis Factor Therapy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Tumor Necrosis Factor-Alpha Inhibitor Treatment for Sarcoidosis

Therapeutics and Clinical Risk Management
2008English

Successful Treatment With Infliximab of a Patient With Tumor Necrosis Factor-Associated Periodic Syndrome (TRAPS) Who Failed to Respond to Etanercept

Journal of Rheumatology
RheumatologyAllergyImmunology
2010English

Tumor Necrosis Factor Α Antagonists in the Treatment of the Patients With Rheumatoid Arthritis

Reumatologia
RheumatologyAllergyImmunology
2012English

Predictors of Treatment Initiation With Tumor Necrosis Factor-Α Inhibitors in Patients With Rheumatoid Arthritis

Journal of Managed Care Pharmacy
2014English

Treatment of Intestinal Behcet's Syndrome With Chimeric Tumour Necrosis Factor Alpha Antibody

Gut
Gastroenterology
2001English

Tumor Necrosis Factor Alpha in Inflammatory Bowel Disease.

Gut
Gastroenterology
1994English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy